Next Generation News and Research

RSS

Zimmer launches UniWallis Posterior Dynamic Stabilization System in Europe and Asia Pacific

Zimmer Holdings, Inc., a global leader in musculoskeletal care, today announced the launch of the next generation of its Wallis® Posterior Dynamic Stabilization System, the UniWallis™ System, in Europe and Asia Pacific. Since the debut of the Wallis System in 2000, feedback collected from surgeons revealed the need for a device that maintains all of the clinical advantages of the Wallis System, provides improved ease of use and offers a more anatomy-sparing procedure.

29 Apr 2011

Sorin launches XTRA autotransfusion system

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, is proud to announce the launch in the U.S. of XTRA, the next-generation of Sorin's autotransfusion (ATS) device family.

29 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.

28 Apr 2011

K2M receives FDA 510(k) clearance for EVEREST Degenerative Spinal System

K2M, Inc., today announced at the International Society for the Advancement of Spine Surgery (SAS) Conference that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the EVEREST™ Degenerative Spinal System, a versatile top-loading polyaxial pedicle screw system featuring the ability to accommodate multiple levels of fixation rigidity to help surgeons individualize patient care.

27 Apr 2011

Durata attains global rights for dalbavancin to treat abSSSI

Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.

26 Apr 2011

BIOBASE introduces new genome sequence custom annotation tool

BIOBASE announced its launch of a new custom annotation tool designed to aid in functional annotation of next generation sequences from uncharacterized genomes.

26 Apr 2011

University of Arkansas receives USDA grant for childhood obesity project

University of Arkansas scientists and educators are attacking childhood obesity in a project funded by a $4.78 million grant for five years from the National Institute of Food and Agriculture of the U.S. Department of Agriculture.

26 Apr 2011

Cedars-Sinai's community benefit contribution is $502.4 million for 2010

Cedars-Sinai Medical Center's financial contribution to community benefit programs and services totaled $502.4 million in fiscal year 2010, reflecting its long-standing mission and dedication to improving community health.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

Oxford Nanopore raises $41 million via private placement of ordinary shares

Oxford Nanopore Technologies Ltd., the UK-based developers of nanopore technology for the direct, electronic analysis of single molecules, today announced that it has raised £25 million in new funding via a private placement of ordinary shares in the Company.

From Oxford Nanopore Technologies 26 Apr 2011

Aquilent launches new vaccine government site to help citizens stay healthy

Aquilent, the recognized leading provider of Web-based solutions shaping the next generation of technology for the federal government, today announced its development support role in the newly launched Vaccines.gov site, under contract with the U.S. Department of Health and Human Services.

26 Apr 2011

HHS awards Eigen two grants from Qualifying Therapeutic Discovery Project

Eigen is the proud recipient of two grant awards from the Qualifying Therapeutic Discovery Project (QTDP) funded by the U.S. Department of Health & Human Services. QTDP tax credits are provided under section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148).

22 Apr 2011

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

U.S. Congressman Rush Holt (R-12th) visited the headquarters of VaxInnate Corporation today, where he congratulated the biotechnology company on having received a U.S. government contract to fund development of the next generation of flu vaccines and called for more technology investments to improve the health of all Americans.

22 Apr 2011

Lovelace Medical Center upgrades to Gamma Knife Perfexion system

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Gamma Knife® Perfexion™ system to Lovelace Medical Center in Albuquerque, New Mexico.

21 Apr 2011

First implantation of blended vitamin E total knee replacement in the U.S

DJO Global, Inc., a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced the implantation of the first blended vitamin E total knee replacement in the U.S.

21 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Axios' bio-based trackable pallet and software technology achieves FDA compliance

Axios Mobile Assets Corporation today announced it has achieved FDA compliance for its proprietary bio-based trackable pallet and software technology. The solutions meet FDA standards for CFR 21 part 11 compliance based on the pallet's material composition, in accordance to the U.S. Federal Code of Regulation.

20 Apr 2011

Gene mutation in Tibetian Terrier dogs causes hereditary form of Parkinson's disease in humans

University of Missouri researchers believe both man and animal will benefit from their discovery that the same gene mutation found in Tibetan Terrier dogs can also be found in a fatal human neurological disorder related to Parkinson's disease.

19 Apr 2011